Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 1999, p. 1393-1400, Vol. 43, No. 6
Center for Research in Anti-Infectives and
Biotechnology, Creighton University School of Medicine, Omaha,
Nebraska 68178
Received 7 August 1998/Returned for modification 23 November
1998/Accepted 31 March 1999
Over the past decade, a number of new
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Use of Microdilution Panels with and without
-Lactamase
Inhibitors as a Phenotypic Test for
-Lactamase Production among
Escherichia coli, Klebsiella spp.,
Enterobacter spp., Citrobacter freundii, and
Serratia marcescens
-lactamases
have appeared in clinical isolates of Enterobacteriaceae
that, unlike their predecessors, do not confer
-lactam resistance
that is readily detected in routine antibiotic susceptibility tests.
Because optimal methodologies are needed to detect these important new
-lactamases, a study was designed to evaluate the
ability of a panel of various
-lactam antibiotics tested alone
and in combination with
-lactamase inhibitors to discriminate between the production of extended-spectrum
-lactamases, AmpC
-lactamases, high levels of
K1
-lactamase, and other
-lactamases in
141 isolates of Escherichia coli,
Klebsiella pneumoniae, Klebsiella oxytoca,
Enterobacter cloacae, Enterobacter aerogenes,
Citrobacter freundii, and Serratia
marcescens possessing well-characterized
-lactamases. The microdilution panels studied contained
aztreonam, cefpodoxime, ceftazidime, cefotaxime, and ceftriaxone, with
and without 1, 2, and 4 µg of clavulanate per ml or 8 µg of
sulbactam per ml and cefoxitin and cefotetan with and without 8 µg of
sulbactam per ml. The results indicated that a minimum panel of five
tests would provide maximum separation of extended-spectrum
-lactamase high AmpC, high K1, and other
-lactamase production in Enterobacteriaceae.
These included cefpodoxime, cefpodoxime plus 4 µg of clavulanate per
ml, ceftazidime, ceftriaxone, and ceftriaxone plus 8 µg of
sulbactam per ml. Ceftriaxone plus 2 µg of clavulanate per ml could
be substituted for cefpodoxime plus 4 µg of clavulanate per ml
without altering the accuracy of the tests. This study indicated that
tests with key
-lactam drugs, alone and in combination with
-lactamase inhibitors, could provide a convenient
approach to the detection of a variety of
-lactamases in
members of the family Enterobacteriaceae.
*
Corresponding author. Mailing address: Center for
Research in Anti-Infectives and Biotechnology, Creighton University
School of Medicine, 2500 California Plaza, Omaha, NE 68178. Phone:
(402) 280-1881. Fax: (402) 280-1225. E-mail:
kstaac{at}creighton.edu.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |